The findings suggest that "supportive care and management of geriatric vulnerabilities at baseline may improve outcomes and ...

Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five ...

Pancreatic cancer survivor Pranathi Perati talks about the importance of clinical trials for patients facing this tough ...

Single-agent adjuvant chemotherapy did not improve overall survival when compared to no adjuvant chemotherapy.

Press Release ImmunoMet Therapeutics, Inc., ("ImmunoMet", or the "Company"), a clinical stage biotechnology company committed to giving patients a novel approach to fight cancer, today provided a data ...

Pancreatic Cancer Action Network Calls for Urgently Needed Research and Funding for Effective Early Detection Strategy and ...

Two U.S. companies teamed up to treat cancer patients using an unproven blood filter in Antigua, out of reach of American ...

Genetic testing is recommended for those with personal and family histories of several types of cancer — including pancreatic ...

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic ...

Adding pamrevlumab to chemotherapy did not improve survival in patients with previously untreated, locally advanced pancreatic cancer.

Gastroenterologist Dr. Rohan Mandaliya of The Center for Comprehensive Pancreatic Care at Mercy goes over the risk factors of ...